SLU-PP-322 — Peptide Dosing Protocols reference
patient_educationexpert_opinion · status: needs_provider_reviewDetails
Summary (generated — provider review required)
SLU-PP-332 Peptide Guide: Dosing, Reconstitution & Endurance (2026) Shop Protocols Stacks A–Z Index Email Updates Home Protocols SLU-PP-332 Peptide Guide: Dosing, Reconstitution & ERR Agonist Research Reference (2026) Protocol / Research Dosing Guide SLU-PP-332 Peptide Guide: Dosing, Reconstitution & ERR Agonist Research Reference (2026) Research guide for SLU-PP-332, the pan-ERR agonist often framed as an exercise mimetic. Covers oral tablet planning, injectable reconstitution math, published murine dosing, side-effect limits, and how it differs from mitochondrial peptides like MOTS-c and AOD-9604. By Garret Grant · Founder & Lead Researcher · Last reviewed June 2026 · Share Supplier Pick Copy code PEPPAL Copy code PEPPAL Verified Supplier Verified Supplier Peptide Partners SLU-PP-332 Oral Tablets View SLU-PP-332 Table of Contents View Supplies Quick Start Mechanism Dosing Protocol & Schedule Supplies Needed Reconstitution Guide Who Should Avoid It Side Effects & Safety Timeline & Monitoring Clinical Evidence Storage & Handling Troubleshooting Regulatory Status SLU-PP-332 Comparisons Related Protocols Blood Tests FAQ References SLU-PP-332 Quick Start Disclaimer This page is an educational research reference and is not medical advice.
The original source document remains the source of truth. Generated summaries are not authoritative.
Linked assets (10) · phenotypes (1)
evidence_reference, dosing_reference, mechanism, safety_reference, monitoring_reference
Phenotypes: mitochondrial_dysfunction
Findings (214) · awaiting review (151)
regulatory · pending
Q7: Is SLU-PP-332 FDA-approved?
dosing · pending
Covers oral tablet planning, injectable reconstitution math, published murine dosing, side-effect limits, and how it differs from mitochondrial peptides like MOTS-c and AOD-9604.
dosing · pending
By Garret Grant · Founder & Lead Researcher · Last reviewed June 2026 · Share Supplier Pick Copy code PEPPAL Copy code PEPPAL Verified Supplier Verified Supplier Peptide Partners SLU-PP-332 Oral Tablets View SLU-PP-332 Table of Contents View Supplies Quick Start Mechanism Dosing Protocol & Schedule Supplies Needed Reconstitution Guide Who Should Avoid It Side Effects & Safety Timeline & Monitoring Clinical Evidence Storage & Handling Troubleshooting Regulatory Status SLU-PP-332 Comparisons Related Protocols Blood Tests FAQ References SLU-PP-332 Quick Start Disclaimer This page is an educational research reference and is not medical advice.
regulatory · pending
SLU-PP-332 is not FDA-approved and has no human clinical trial program as of June 2026.
dosing · pending
No information on this page is intended as a personal dosing recommendation.
mechanism · pending
olecule pan-agonist of the estrogen-related receptors (ERRα, ERRβ, and ERRγ) .
mechanism · pending
ERRs are nuclear receptors that sit upstream of mitochondrial biogenesis, fatty acid oxidation, and the aerobic gene program activated by endurance exercise.
dosing · pending
Research-grade suppliers carry SLU-PP-332 in two main formats: 50 mg oral tablets (commonly sold as a 60-count bottle) and injectable vials at 5 mg or 10 mg strengths.
dosing · pending
Format Primary research format is a 50 mg oral tablet (60-count bottle).
dosing · pending
Injection vials of 5 mg and 10 mg are also available.
dosing · pending
Schedule Mouse studies used twice daily intraperitoneal injection.
dosing · pending
Community oral protocols are typically once daily; no human dosing schedule has been clinically validated.
dosing · pending
Measure For tablets, dose count and bottle count drive supplies math.
mechanism · pending
When you run, muscle cells upregulate these same receptors.
mechanism · pending
ERRα agonism — the primary driver ERRα is highly expressed in energy-demanding tissues such as skeletal muscle, heart, brown adipose tissue, and liver.
dosing · pending
In the Billon 2023 paper, a single 25 mg/kg intraperitoneal dose in mice was enough to induce an acute aerobic exercise transcriptional signature in muscle within hours.
outcome · pending
Together they drive expression of nuclear-encoded mitochondrial genes, increasing both the number and efficiency of mitochondria in muscle and cardiac tissue.
dosing · pending
The trade-off is unknown oral bioavailability — in animal studies, every efficacy dose was delivered by intraperitoneal injection, not by mouth.
dosing · pending
In the Billon 2023 study, 50 mg/kg twice daily for 28 days increased succinate dehydrogenase-positive oxidative muscle fibers and raised OXPHOS complex protein levels.
dosing · pending
Fatty acid oxidation In diet-induced obese mice and ob/ob mice, 50 mg/kg twice daily for 28 days increased whole-body energy expenditure and fatty acid oxidation, reduced fat mass, lowered cholesterol and triglycerides, and improved insulin sensitivity without changing food intake .
mechanism · pending
That is a metabolic-rate mechanism, not an appetite-suppression mechanism like Semaglutide or Tirzepatide .
outcome · pending
ERRγ and cardiac metabolism In a pressure-overload heart-failure mouse model, six weeks of SLU-PP-332 improved ejection fraction, reduced fibrosis, and increased survival.
mechanism · pending
The practical takeaway is that ERRα appears to drive most skeletal-muscle effects, while ERRγ carries more of the cardiac signal.
dosing · pending
SLU-PP-332 Dosing Protocol & Schedule Before any numbers: every published in-vivo dose for SLU-PP-332 is a mouse dose.
dosing · pending
There is no human titration schedule, no human pharmacokinetic study, no human safety margin, and no FDA-approved label.
dosing · pending
Human dosing figures circulating in the research community are either human-equivalent-dose extrapolations from mouse protocols or vendor-driven tablet/capsule suggestions with no primary-source backing.
dosing · pending
The dosing guide below is split into the two formats actually available from research suppliers: oral tablets (the most common consumer-research format) and injectable vials (the format used in published animal studies).
dosing · pending
Oral Tablet Injectable Vial For the 50 mg / 60-count oral tablet form sold by research suppliers.
dosing · pending
The current featured supplier carries SLU-PP-332 as a 50 mg tablet in a 60-tablet bottle .
dosing · pending
Oral bioavailability in humans has not been formally published, so any dose number here is a community-pattern reference, not a clinically validated dose.
dosing · pending
Community Oral Tablet Dosing Patterns Pattern Low-dose / micro-dose D
dosing · pending
aily Dose ≤1.5 mg Tablet Math (50 mg) Not practical with a 50 mg tablet — typically uses smaller-strength vendor capsules instead Frequency Once daily Notes Common starting pattern in community oral protocols.
dosing · pending
Pattern Mid-dose Daily Dose 25 mg (½ tablet) Tablet Math (50 mg) 0.5 tablet/day → ~120 days from one 60-tablet bottle Frequency Once daily Notes Splitting a scored tablet; community-derived only.
dosing · pending
Pattern Standard supplier-tablet dose Daily Dose 50 mg (1 tablet) Tablet Math (50 mg) 1 tablet/day → ~60 days from one bottle Frequency Once daily Notes Anchored to the supplier's 50 mg tablet strength.
dosing · pending
Pattern Higher community pattern Daily Dose 100 mg (2 tablets) Tablet Math (50 mg) 2 tablets/day → ~30 days from one bottle Frequency Once or split twice daily Notes Reported informally; no controlled data.
dosing · pending
Pattern HED extrapolation ceiling Daily Dose ~650 mg/day Tablet Math (50 mg) 13 tablets/day — included only to show the gap with vendor doses Frequency n/a Notes Allometric scaling from 100 mg/kg/day mouse dose to 80 kg human.
dosing · pending
Not a recommendation; no human safety data exists at any dose.
dosing · pending
Pattern Daily Dose Tablet Math (50 mg) Frequency Notes Low-dose / micro-dose ≤1.5 mg Not practical with a 50 mg tablet — typically uses smaller-strength vendor capsules instead Once daily Common starting pattern in community oral protocols.
dosing · pending
Mid-dose 25 mg (½ tablet) 0.5 tablet/day → ~120 days from one 60-tablet
dosing · pending
bottle Once daily Splitting a scored tablet; community-derived only.
Processing
Processed into 36 searchable sections.